In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose-to-brain drug delivery
- PMID: 36736328
- DOI: 10.1002/bdd.2348
In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose-to-brain drug delivery
Abstract
The intranasal route of administration provides a noninvasive method to deliver drugs into the systemic circulation and/or directly into the brain. Direct nose-to-brain drug delivery offers the possibility to treat central nervous system diseases more effectively, as it can evade the blood-brain barrier. In vitro and ex vivo intranasal models provide a means to investigate physiological and pharmaceutical factors that could play a role in drug delivery across the nasal epithelium as well as to determine the mechanisms involved in drug absorption from the nose. The development and implementation of cost-effective pharmacokinetic models for intranasal drug delivery with good in vitro-in vivo correlation can accelerate pharmaceutical drug product development and improve economic and ecological aspects by reducing the time and costs spent on animal studies. Special considerations should be made with regard to the purpose of the in vitro/ex vivo study, namely, whether it is intended to predict systemic or brain delivery, source and site of tissue or cell sampling, viability window of selected model, and the experimental setup of diffusion chambers. The type of model implemented should suit the relevant needs and requirements of the project, researcher, and interlaboratory. This review aims to provide an overview of in vitro and ex vivo models that have been developed to study intranasal and direct nose-to-brain drug delivery.
Keywords: ex vivo experimental models; experimental models; in vitro experimental models; intranasal drug delivery; nose-to-brain drug delivery.
© 2023 The Authors. Biopharmaceutics & Drug Disposition published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Abdulla, N. A., Balata, G. F., El-ghamry, H. A., & Gomaa, E. (2021). Intranasal delivery of Clozapine using nanoemulsion-based in-situ gels: An approach for bioavailability enhancement. Saudi Pharmaceutical Journal, 29(12), 1466-1485. https://doi.org/10.1016/j.jsps.2021.11.006
-
- Agu, R. U., & Ugwoke, M. I. (2008). In situ and ex vivo nasal models for preclinical drug development studies. In C. Ehrhard & K.-J. Kim (Eds.), Drug absorption studies: In situ, in vitro and in silico models (Vol. 7, pp. 112-134). Springer. https://doi.org/10.1007/978-0-387-74901-3_5
-
- Albarki, M. A., & Donovan, M. D. (2020). Bigger or smaller? Size and loading effects on nanoparticle uptake efficiency in the nasal mucosa. AAPS PharmSciTech, 21(8), 294. https://doi.org/10.1208/s12249-020-01837-3
-
- Arisoy, S., Sayiner, O., Comoglu, T., Onal, D., Atalay, O., & Pehlivanoglu, B. (2020). In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery. Pharmaceutical Development and Technology, 25(6), 735-747. https://doi.org/10.1080/10837450.2020.1740257
-
- Bahadur, S., & Pathak, K. (2012). Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opinion on Drug Delivery, 9(1), 19-31. https://doi.org/10.1517/17425247.2012.636801
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources